Movement Alert｜Akeso Falls 3.06% in Regular Trading, Technical Profit-Taking After Previous Session 13% Rally Amid Sector-Wide Weakness

Market Focus06-30

On June 30, Akeso (09926.HK) declined 3.06% in regular trading, trading at HKD 88.8/share, with turnover of HKD 276 million. The decline follows a nearly 13% surge in the previous session driven by dual catalysts: its core product Ivonescimab topping Evaluate's global most valuable pipeline ranking with a risk-adjusted NPV exceeding USD 25.2 billion, and the completion of the first nationwide batch delivery of new drug Qiyoukang.

Today's pullback represents technical profit-taking after the sharp rally. The stock has cumulatively retreated over 30% from its post-ASCO data peak, and despite the company's HKD 200 million share buyback plan and management stake increases providing support, short-term selling pressure remains incompletely absorbed.

The broader biotechnology sector weighed on sentiment, with peers BeiGene down 2.12%, Remegen down 3.76%, and Transthera down 4.25%, reflecting sector-wide beta pressure that amplified individual stock adjustment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1194090041?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-30 10:08","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1194090041","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Akeso Falls 3.06% in Regular Trading, Technical Profit-Taking After Previous Session 13% Rally Amid Sector-Wide Weakness","media":"Market Focus","content":"<p><p>On June 30, Akeso (09926.HK) declined 3.06% in regular trading, trading at HKD 88.8/share, with turnover of HKD 276 million. The decline follows a nearly 13% surge in the previous session driven by dual catalysts: its core product Ivonescimab topping Evaluate's global most valuable pipeline ranking with a risk-adjusted NPV exceeding USD 25.2 billion, and the completion of the first nationwide batch delivery of new drug Qiyoukang.</p><p>Today's pullback represents technical profit-taking after the sharp rally. The stock has cumulatively retreated over 30% from its post-ASCO data peak, and despite the company's HKD 200 million share buyback plan and management stake increases providing support, short-term selling pressure remains incompletely absorbed.</p><p>The broader biotechnology sector weighed on sentiment, with peers BeiGene down 2.12%, Remegen down 3.76%, and Transthera down 4.25%, reflecting sector-wide beta pressure that amplified individual stock adjustment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Akeso Falls 3.06% in Regular Trading, Technical Profit-Taking After Previous Session 13% Rally Amid Sector-Wide Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Akeso Falls 3.06% in Regular Trading, Technical Profit-Taking After Previous Session 13% Rally Amid Sector-Wide Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-30 10:08</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 30, Akeso (09926.HK) declined 3.06% in regular trading, trading at HKD 88.8/share, with turnover of HKD 276 million. The decline follows a nearly 13% surge in the previous session driven by dual catalysts: its core product Ivonescimab topping Evaluate's global most valuable pipeline ranking with a risk-adjusted NPV exceeding USD 25.2 billion, and the completion of the first nationwide batch delivery of new drug Qiyoukang.</p><p>Today's pullback represents technical profit-taking after the sharp rally. The stock has cumulatively retreated over 30% from its post-ASCO data peak, and despite the company's HKD 200 million share buyback plan and management stake increases providing support, short-term selling pressure remains incompletely absorbed.</p><p>The broader biotechnology sector weighed on sentiment, with peers BeiGene down 2.12%, Remegen down 3.76%, and Transthera down 4.25%, reflecting sector-wide beta pressure that amplified individual stock adjustment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09926","symbol_name":"康方生物","start_time":0,"source_url":"","article_id":"1194090041","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1194090041","pubTimestamp":1782785320,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 30, Akeso (09926.HK) declined 3.06% in regular trading, trading at HKD 88.8/share, with turnover of HKD 276 million. The decline follows a nearly 13% surge in the previous session driven by...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09926":"康方生物"},"translate_title":"走势提示|康方生物常规交易下跌3.06%，前一交易日上涨13%后出现技术性获利了结，板块整体疲软","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09926":1},"content_text":"On June 30, Akeso (09926.HK) declined 3.06% in regular trading, trading at HKD 88.8/share, with turnover of HKD 276 million. The decline follows a nearly 13% surge in the previous session driven by dual catalysts: its core product Ivonescimab topping Evaluate's global most valuable pipeline ranking with a risk-adjusted NPV exceeding USD 25.2 billion, and the completion of the first nationwide batch delivery of new drug Qiyoukang.Today's pullback represents technical profit-taking after the sharp rally. The stock has cumulatively retreated over 30% from its post-ASCO data peak, and despite the company's HKD 200 million share buyback plan and management stake increases providing support, short-term selling pressure remains incompletely absorbed.The broader biotechnology sector weighed on sentiment, with peers BeiGene down 2.12%, Remegen down 3.76%, and Transthera down 4.25%, reflecting sector-wide beta pressure that amplified individual stock adjustment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1194090041","isCrawlerRequest":true}